LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $9.00 at BTIG Research

LifeStance Health Group (NASDAQ:LFST) had its price objective increased by BTIG Research from $8.00 to $9.00 in a report issued on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

LFST has been the topic of several other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of LifeStance Health Group in a research report on Wednesday, October 8th. Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday. UBS Group upped their target price on shares of LifeStance Health Group from $8.50 to $9.00 and gave the company a “buy” rating in a research report on Friday, August 8th. Finally, Wall Street Zen lowered LifeStance Health Group from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.83.

LifeStance Health Group Price Performance

Shares of LFST stock traded up $0.04 during trading hours on Thursday, hitting $6.29. The stock had a trading volume of 4,297,370 shares, compared to its average volume of 1,993,876. LifeStance Health Group has a one year low of $3.74 and a one year high of $8.30. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.48 and a quick ratio of 1.48. The stock’s 50-day moving average price is $5.29 and its two-hundred day moving average price is $5.27. The stock has a market capitalization of $2.45 billion, a price-to-earnings ratio of -125.80 and a beta of 1.15.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. LifeStance Health Group had a negative return on equity of 1.11% and a negative net margin of 1.23%.The company had revenue of $363.81 million during the quarter, compared to analyst estimates of $355.06 million. During the same period in the prior year, the company earned ($0.02) earnings per share. The firm’s revenue was up 16.3% on a year-over-year basis. LifeStance Health Group has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts forecast that LifeStance Health Group will post -0.18 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Summit Partners L. P sold 8,407,643 shares of the business’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the completion of the transaction, the insider owned 33,524,715 shares in the company, valued at $169,970,305.05. The trade was a 20.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Darren M. Black sold 8,407,643 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $5.07, for a total value of $42,626,750.01. Following the completion of the sale, the director owned 33,524,715 shares in the company, valued at approximately $169,970,305.05. The trade was a 20.05% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 20,407,643 shares of company stock valued at $103,466,750. Insiders own 3.20% of the company’s stock.

Institutional Trading of LifeStance Health Group

Several hedge funds have recently modified their holdings of LFST. DekaBank Deutsche Girozentrale acquired a new stake in LifeStance Health Group during the 1st quarter worth about $31,000. Park Edge Advisors LLC acquired a new position in shares of LifeStance Health Group in the 2nd quarter valued at $52,000. Bayesian Capital Management LP purchased a new stake in LifeStance Health Group during the second quarter worth $52,000. Xponance Inc. acquired a new stake in LifeStance Health Group during the first quarter valued at $69,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in LifeStance Health Group during the second quarter valued at $70,000. 85.50% of the stock is owned by hedge funds and other institutional investors.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.